Replies to post #262 on Camaro1093 Stocks!

[TenaciousD]

lol I stay because of this ! If approved, ANX-530 threatens to take market share away from several bigger pharmaceutical companies, including GlaxoSmithKline. This could mean a huge upside to the current share price, especially since the Company has no debt and a low float, as well as millions in cash on hand. Among ADVENTRX's top institutional holders are Carl Icahn's Icahn Capital Management, Renaissance Technologies, UBS AG, the Bank of New York Mellon and Barclay's Global Investors. Beacon Equity Research has the stock listed as "Bullish."

Have a great weekend bbb

D

[Camaro1093]

lol. I agree. AF bashed CTIC @ .20-.30 as well, later on it went up to $2. IMO, ANX will do the same thing.

GL.